Project Grant HT94252410684
Award Date
9/1/24
Completion Date
8/31/28
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
This federal Project Grant award in the amount of $1,599,743 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research to identify and overcome resistance after donor-derived ex vivo expanded natural killer (NK) cell therapy and haploidentical hematopoietic cell transplantation in children and young adults with high-risk acute myeloid leukemia (AML). The research, conducted by the primary awardee...
The Project Grant award of $624,000 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program to the Research Institute at Nationwide Children's Hospital. The funding supports a project titled "SPLICING UP PD-L1 FOR IMMUNOTHERAPY ENHANCEMENT IN PEDIATRIC NEURONAL TUMORS" over a two-year period from September 30, 2023 to September 29, 2025. The goal is to conduct research to advance immunotherapy approaches...
This $655,000 Project Grant award to The Johns Hopkins University from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports research to identify and circumvent resistance after donor-derived ex vivo expanded natural killer (NK) cells and haploidentical hematopoietic cell transplantation (haplo-HCT) in children and young adults with high-risk acute myeloid leukemia (AML). The award period runs from September 1, 2024 to...
This federal Project Grant award of $1,317,452.00 from the Defense Health Agency (DHA) was provided to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 4-year research project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" that commenced on August 15, 2023 and is scheduled for completion by August 14, 2027. The Research Institute at Nationwide Children's...
The federal Project Grant award, with the ID HT94252510356, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $624,000.00 award will fund comprehensive in vivo phenotyping research on fusion-driven pediatric rhabdomyosarcomas conducted by the Research Institute at Nationwide Children's Hospital (RINCH), a prominent non-profit research organization. The research aims to advance the understanding and treatment...
This $713,818 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to characterize novel patient-specific modeling systems for NF2 disease research and therapeutic testing. The project will be conducted from September 1, 2024 through August 31, 2027. The Research Institute has extensive experience delivering federal research...
The Defense Health Agency awarded a $1,249,009 Project Grant to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2023, funds a 4-year project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" to conduct medical research and development related to improving treatments for glioma, a type of brain cancer. As a non-profit research institute, the...
The federal Project Grant award in the amount of $5,149,107.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Fred Hutchinson Cancer Center in Seattle, WA in defining human correlates of super-evasive disseminated tumor cells, understanding their pathological relevance, and developing methods to eradicate them. This advanced biomedical research project aligns with the program's focus on transforming...
This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
This $1,561,794 Project Grant was awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports research led by the University of Cincinnati to investigate the role of plasmacytoid dendritic cells (pDCs) in immune suppression and treatment resistance in acute myeloid leukemia. The award will fund a 3-year research project from September 2024 through August 2027 to advance the scientific understanding of how pDCs...